U.S. markets closed
  • S&P Futures

    4,121.25
    +1.00 (+0.02%)
     
  • Dow Futures

    33,652.00
    +21.00 (+0.06%)
     
  • Nasdaq Futures

    13,819.25
    +10.50 (+0.08%)
     
  • Russell 2000 Futures

    2,228.00
    -2.60 (-0.12%)
     
  • Crude Oil

    59.97
    +0.27 (+0.45%)
     
  • Gold

    1,735.90
    +3.20 (+0.18%)
     
  • Silver

    24.94
    +0.08 (+0.31%)
     
  • EUR/USD

    1.1906
    -0.0011 (-0.10%)
     
  • 10-Yr Bond

    1.6750
    +0.0090 (+0.54%)
     
  • Vix

    16.91
    +0.22 (+1.32%)
     
  • GBP/USD

    1.3738
    -0.0004 (-0.03%)
     
  • USD/JPY

    109.6350
    +0.2590 (+0.24%)
     
  • BTC-USD

    61,013.88
    +1,061.20 (+1.77%)
     
  • CMC Crypto 200

    1,301.53
    +6.95 (+0.54%)
     
  • FTSE 100

    6,889.12
    -26.63 (-0.39%)
     
  • Nikkei 225

    29,848.41
    +309.68 (+1.05%)
     

Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Live Webcast will be on September 14, 2020

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

(PRNewsfoto/Neurocrine Biosciences, Inc.)
(PRNewsfoto/Neurocrine Biosciences, Inc.)

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-conference-301125819.html

SOURCE Neurocrine Biosciences, Inc.